SLT (CognivAiD™) Improves Memory and Cognition in Individuals With Mild Cognitive Impairment: Clinical Trial Results
- Investigator-initiated clinical trial of SLT (CognivAiD™) for mild cognitive impairment, led by Western Sydney University’s NICM Health Research Institute.
- Trial results reported that CognivAiD™ significantly improved key cognitive domains of episodic memory and executive function, and was well-tolerated.
SINGAPORE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Moleac, a biopharmaceutical company pioneering innovative therapeutics in neurology, announced promising results from an investigator-led clinical trial conducted on SLT (CognivAiD™) in mild cognitive impairment (MCI). Individuals with MCI are at increased risk of developing dementia later on. MCI may also be an early manifestation of neurodegenerative disorders such as vascular dementia (VaD) and Alzheimer’s disease.1 Therapeutic options for MCI are few, have modest benefits, and are often associated with undesirable side effects.2,3,4
In the study reported by Professor Geneviève Steiner-Lim and team in Alzheimer’s & Dementia: Translational Research and Clinical Interventions, CognivAiD™ improved memory and cognitive abilities such as memory retrieval and executive functions (multi-tasking and complex attention).5
“Our findings are very promising as they show that even after a relatively short treatment period of just 12 weeks, SLT can support important aspects of memory and thinking in people with mild cognitive impairment. It is also well-tolerated. Early intervention is critical in order to delay or prevent a dementia diagnosis,” said A/Prof Geneviève Steiner-Lim, lead investigator of the investigator-initiated trial, in the media release by NICM Health Research Institute.6
“This investigator-led study expands our understanding of our product and its potential applications. The new data complements the existing use of CognivAiD™ for vascular dementia as it can now also benefit patients with MCI as early as possible before their symptoms further develop, and before possible dementia onset. This is a big advancement and we would like to thank the researchers and the patients who participated in the trial,” said David Picard, CEO of Moleac.
With this latest finding, CognivAiD™ represents a promising therapeutic option to address a significant unmet medical need for people with MCI, expanding its current indication for patients with VaD. It is estimated that about 17% of individuals aged 60 and above are affected by MCI.7
For more information, please visit www.cognivaid.com.
Launched in October 2022, CognivAiD™ is an evidence-based formulation comprising active extracts from Croci Stigma, Ginkgo Folium and Ginseng Radix et Rhizoma. CognivAiD™ has demonstrated safety and efficacy in vascular dementia and mild cognitive impairment. CognivAiD™ is a trademark of Moleac and is referred to as ‘SLT’ and ‘MLC-SLT’.
Moleac is a biopharmaceutical company committed to helping patients and families reconnect with their lives. Headquartered in Singapore, we are dedicated to developing scientifically proven innovative formulations that bridge therapeutic gaps and address unmet needs of patients with neurological conditions such as stroke, traumatic brain injuries and dementia.
Moleac’s flagship product NeuroAiD™II benefits more than 40,000 patients in over 35 countries every year.
For more information, please visit www.moleac.com.
Name of Press Contact: Clement Dif
Phone: +65 6211 3710
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant7.12.2023 07:35:00 CET | Press release
Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd aloneFirst global Phase 3 study to report positive results with an anti-CD38 therapy in combination with VRd in transplant-ineligible patients, reinforcing the potential for Sarclisa as a best-in-class medicineStudy results will be submitted for presentation at an upcoming medical meeting and form the basis of a future regulatory submission PARIS, December 7, 2023. The Phase 3 IMROZ trial evaluating the investigational use of Sarclisa® (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) met its primary endpoint at a planned interim analysis for efficacy, demonstrating statistically significant improvement in progression-free surviva
Avance Gas Holding Ltd: Ex Dividend USD 0.50 today7.12.2023 07:01:00 CET | Press release
Hamilton, Bermuda, December 7, 2023 The shares in Avance Gas Holding Ltd (ticker: "AGAS") will be traded ex-dividend USD 0.50 as of today relating to the dividend for the third quarter of 2023. The dividend will be paid on December 15, 2023. For further information, please contact: Randi Navdal Bekkelund - Chief Financial Officer Tel: +47 23 11 40 00 Email: IR@avancegas.com ABOUT AVANCE GAS Avance Gas operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carriers (VLGCs) and operates a fleet of fourteen modern ships including two dual fuel LPG newbuildings for delivery in early 2024 as well as four medium sized gas/ammonia carriers due for delivery in 2025 and 2026. For more information about Avance Gas, please visit www.avancegas.com. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook7.12.2023 07:00:00 CET | Press release
PARIS, FRANCE, 7 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K. “Ipsen has made significant progress since our strategic roadmap was implemented three years ago and is today in a great spot,” commented David Loew, Chief Executive Officer, Ipsen. “Our business has been transformed, with the focus on Specialty Care now supported by a stronger pipeline and momentum from our growth platforms, as well as a robust balance sheet and an external-innovation strategy yielding compelling results. Ipsen is now ready for its next phase of growth with several launches across multiple potential indications, providing more options for patients with high unmet medical needs. Our journey will be driven by the combination of the growth platforms, our new medicines and more external-innovation transactions to come. We will also continue to deliver on our ambitious sustainability objectives and road
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC7.12.2023 07:00:00 CET | Press release
New Drug Application granted priority review with PDUFA date set for June 10, 2024 European Medicines Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor Investigational elafibranor is the first novel second-line treatment for primary biliary cholangitis (PBC) to be filed in E.U. and U.S. in nearly a decade PARIS, FRANCE, 07 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational elafibranor. An oral, once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, investigational elafibranor could potentially be the first novel second-line treatment for the rare, cholestatic liver disease, PBC, in nearly a decade. The target FDA PDUFA date under priority review is June 10, 2024. The European Medicines Agency (EMA) has also validated Ipsen’s Marketing Authorization Applica
Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage7.12.2023 07:00:00 CET | Press release
Pratteln, Switzerland, December 7, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the promotion of Geert Jan van Daal, MD, PhD, to Chief Commercial Officer (CCO) and of Marc Schrader to Chief Technology Officer (CTO). Both will join the six-member Executive Committee effective January 1, 2024. “Santhera is transitioning to the commercial phase and will make AGAMREE® (vamorolone) available to patients in Europe starting in Germany in early 2024, subject to approval by the European Commission. In a staged roll-out across the key European markets, launches will follow in the UK and France later that year, with Spain and Italy scheduled to launch in early 2025,” said Dario Eklund, CEO of Santhera. “With Geert Jan and Marc joining the Executive Committee, we are leveraging the existing expertise within our leadership team and are elevating the commercial and supply chain functions to their level of importance as we enter the commercial market.” Geert Jan van Daal, MD, PhD, has held v